232 related articles for article (PubMed ID: 18301797)
1. Epigenome-derived drugs: recent advances and future perspectives.
Vogiatzi P; Aimola P; Scarano MI; Claudio PP
Drug News Perspect; 2007 Dec; 20(10):627-33. PubMed ID: 18301797
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic opportunities and challenges in cancer.
Best JD; Carey N
Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
[TBL] [Abstract][Full Text] [Related]
3. Some thoughts on experimental screening.
Carter SK
Biomedicine; 1975 Jan; 22(1):5-17. PubMed ID: 1101978
[TBL] [Abstract][Full Text] [Related]
4. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
5. Rational drug design.
Mandal S; Moudgil M; Mandal SK
Eur J Pharmacol; 2009 Dec; 625(1-3):90-100. PubMed ID: 19835861
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
Grønbaek K; Treppendahl M; Asmar F; Guldberg P
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
[TBL] [Abstract][Full Text] [Related]
7. Chemical approaches to the discovery and development of cancer therapies.
Neidle S; Thurston DE
Nat Rev Cancer; 2005 Apr; 5(4):285-96. PubMed ID: 15803155
[TBL] [Abstract][Full Text] [Related]
8. Scaffold/matrix attachment regions (S/MARs): relevance for disease and therapy.
Gluch A; Vidakovic M; Bode J
Handb Exp Pharmacol; 2008; (186):67-103. PubMed ID: 18491049
[TBL] [Abstract][Full Text] [Related]
9. New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma.
Burton JD; Goldenberg DM
Expert Opin Emerg Drugs; 2010 Dec; 15(4):569-83. PubMed ID: 20828225
[TBL] [Abstract][Full Text] [Related]
10. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
Perry WL; Weitzman A
Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
[TBL] [Abstract][Full Text] [Related]
11. Rational combinations using HDAC inhibitors.
Bots M; Johnstone RW
Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
[TBL] [Abstract][Full Text] [Related]
12. The contemporary drug development process: advances and challenges in preclinical and clinical development.
Garrett MD; Walton MI; McDonald E; Judson I; Workman P
Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic deregulation of DNA repair and its potential for therapy.
Hegi ME; Sciuscio D; Murat A; Levivier M; Stupp R
Clin Cancer Res; 2009 Aug; 15(16):5026-31. PubMed ID: 19671858
[TBL] [Abstract][Full Text] [Related]
14. Improving the evaluation of new cancer treatments: challenges and opportunities.
Rothenberg ML; Carbone DP; Johnson DH
Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
[TBL] [Abstract][Full Text] [Related]
15. Prodrug strategies in anticancer chemotherapy.
Kratz F; Müller IA; Ryppa C; Warnecke A
ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
17. [Target selectivity of anticancer drugs].
Fattoruso SI; Di Lauro L; Conti F; Amodio A; Lopez M
Clin Ter; 2008; 159(3):189-206. PubMed ID: 18594750
[TBL] [Abstract][Full Text] [Related]
18. Strategies for optimizing combinations of molecularly targeted anticancer agents.
Dancey JE; Chen HX
Nat Rev Drug Discov; 2006 Aug; 5(8):649-59. PubMed ID: 16883303
[TBL] [Abstract][Full Text] [Related]
19. Delivery of epidrugs.
el Bahhaj F; Dekker FJ; Martinet N; Bertrand P
Drug Discov Today; 2014 Sep; 19(9):1337-52. PubMed ID: 24680930
[TBL] [Abstract][Full Text] [Related]
20. Non-mammalian models for epigenetic analyses in cancer.
Schaefer M; Meusburger M; Lyko F
Hum Mol Genet; 2007 Apr; 16 Spec No 1():R1-6. PubMed ID: 17613542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
